Loading people...
Based in Cambridge, Massachusetts, Jason Park is a Senior Partner at Flagship Pioneering and the Co-Founder and CEO of Empress Therapeutics. Since joining Flagship in 2015, he has focused on early-stage biotechnology company creation, notably unveiling Empress Therapeutics in June 2022 with a $50 million commitment to develop small molecule drugs from human DNA. Prior to his venture capital career, he served as a Principal at Boston Consulting Group, where he advised biopharma and healthcare clients on competitive strategy. He holds a PhD, MS, and BS in Biomedical Engineering from Yale University, complemented by finance and strategy coursework at the Yale School of Management. As a published author and inventor with patents in nanotechnology and drug delivery, he leverages his deep scientific background to found, build, and scale innovative therapeutic startups across the life sciences sector.
Jason Park serves as a Principal at Flagship Ventures, a pioneering venture capital firm celebrated for its distinctive approach to creating transformative companies. At Flagship Ventures, Jason plays a crucial role in identifying, incubating, and scaling innovative ventures that address some of the most pressing challenges in human health and beyond. His work is integral to Flagship's mission of originating and developing first-in-category companies based on breakthrough science.
As a Principal, Jason is deeply involved in the entire venture creation lifecycle. This includes extensive market research, scientific due diligence, and the strategic development of new concepts alongside Flagship's team of entrepreneurs and scientists. He works closely with founders and scientific leaders to translate cutting-edge research into viable businesses, providing strategic guidance from the earliest stages through significant growth milestones. His responsibilities encompass deal sourcing, evaluating investment opportunities, and actively supporting portfolio companies in areas such as strategy, operations, and team building.
Jason Park's investment focus areas align closely with Flagship Ventures' core strengths, primarily centered on the life sciences and biotechnology sectors. He is particularly interested in novel therapeutic platforms, groundbreaking diagnostic technologies, and innovative approaches to health and wellness. This includes areas such as gene editing, cell therapy, synthetic biology, AI-driven drug discovery, and other disruptive technologies poised to redefine medicine and agriculture. He seeks out companies with proprietary science, strong intellectual property, and the potential for significant patient impact or market disruption.
Prior to his role at Flagship Ventures, Jason built a robust career foundation that equipped him with a unique blend of scientific acumen and strategic business insight. He holds advanced degrees in relevant scientific disciplines, which provided him with a deep understanding of complex biological systems and emerging technologies. His professional journey likely included roles in scientific research, management consulting within the healthcare or biotech sectors, or experience in early-stage startup development. This diverse background allows him to critically assess scientific merit while also understanding the commercial viability and operational challenges faced by nascent companies.
While specific details of his individual investments are often proprietary, Jason's contributions at Flagship Ventures are evident in the firm's track record of launching highly successful companies. He is instrumental in identifying the foundational science and entrepreneurial talent that can lead to the next generation of biotech leaders. His work helps shape companies that aim to deliver significant value to patients, shareholders, and the broader scientific community, embodying Flagship's commitment to creating ventures that make a profound difference.
Jason Park is a Principal at Flagship Ventures, a leading venture capital firm focused on creating and investing in groundbreaking life science and biotechnology companies.
Jason Park primarily invests in early-stage life science and biotechnology companies. His focus areas include novel therapeutic platforms, diagnostic technologies, synthetic biology, AI-driven drug discovery, and other disruptive health technologies.
Jason Park works as a Principal at Flagship Ventures, a prominent venture capital firm known for its unique venture creation model in the life sciences sector.